• Explore /
  • Poster
  • / Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early stage breast cancer (NCT01372579).

Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early stage breast cancer (NCT01372579).

Abstract Poster

Authors

null

Virginia G. Kaklamani

Northwestern University Division of Hematology/Oncology, Chicago, IL

Virginia G. Kaklamani , Elisha Hughes , Kalliopi P. Siziopikou , Kirsten Timms , Victor Abkevich , Cara Solimeno , Anne-Renee Hartman , Jacqueline Jeruss , Caitlin Meservey , Borko Jovanovic , Irene B. Helenowski , Seema Kahn , Kevin P. Bethke , Nora Hansen , Regina Uthe , Steven Rosen , Kent Hoskins , Jamie Von Roenn , Sarika Jain , William John Gradishar

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy

Track

Breast Cancer

Sub Track

Triple-Negative Breast Cancer

Clinical Trial Registration Number

NCT01372579

Citation

J Clin Oncol 33, 2015 (suppl; abstr 1017)

DOI

10.1200/jco.2015.33.15_suppl.1017

Abstract #

1017

Poster Bd #

131

Abstract Disclosures

Similar Posters

First Author: Oleg Gluz

First Author: Kenji Tamura

First Author: Lee Steven Schwartzberg

Poster

2024 ASCO Genitourinary Cancers Symposium

SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline <em>BRCA1/2</em> mutations.

SWOG S2210: A phase II study of neoadjuvant carboplatin for localized, high-risk prostate cancer with germline BRCA1/2 mutations.

First Author: Heather H. Cheng